FOLD * Stock Overview
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Amicus Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$208.80 |
| 52 Week High | US$233.00 |
| 52 Week Low | US$208.80 |
| Beta | 0.81 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -28.62% |
| 5 Year Change | n/a |
| Change since IPO | -5.51% |
Recent News & Updates
Recent updates
Shareholder Returns
| FOLD * | MX Biotechs | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how FOLD * performed against the MX Biotechs industry.
Return vs Market: Insufficient data to determine how FOLD * performed against the MX Market.
Price Volatility
| FOLD * volatility | |
|---|---|
| FOLD * Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: FOLD * has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine FOLD *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 484 | Brad Campbell | amicusrx.com |
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. The company also develops AT-GAA, a novel treatment paradigm for Pompe disease; and enzyme replacement therapies for Pompe diseases.
Amicus Therapeutics, Inc. Fundamentals Summary
| FOLD * fundamental statistics | |
|---|---|
| Market cap | Mex$58.36b |
| Earnings (TTM) | -Mex$4.27b |
| Revenue (TTM) | Mex$5.95b |
9.8x
P/S Ratio-13.7x
P/E RatioIs FOLD * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FOLD * income statement (TTM) | |
|---|---|
| Revenue | US$329.23m |
| Cost of Revenue | US$38.60m |
| Gross Profit | US$290.63m |
| Other Expenses | US$527.20m |
| Earnings | -US$236.57m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.83 |
| Gross Margin | 88.28% |
| Net Profit Margin | -71.85% |
| Debt/Equity Ratio | 318.6% |
How did FOLD * perform over the long term?
See historical performance and comparison